Cyprotex to expand its UK facility into BioHub at Alderley Park
Will provide additional capacity for laboratories and office space
Cyprotex, a UK specialist ADME-Tox Contract Research Organisation, has announced plans for the expansion of its UK facility into BioHub, a new bioscience centre at AstraZeneca’s Alderley Park research campus in Cheshire.
BioHub will provide Cyprotex with additional capacity for laboratories and office space. The new laboratories include fully equipped cell culture facilities and radiochemical handling capabilities enabling the firm to continue its growth strategy into new areas supporting preclinical drug discovery projects.
This expansion follows the firm's encouraging growth figures in the first six months of the year, with a revenue increase of 22.3% in the first half compared with the same period in 2012 and a record half yearly operating profit of £317,000. The firm said performance remains strong across all of its geographical markets and its main service operations of high throughput ADME, customised ADME and toxicology.
Anthony Baxter, Cyprotex’s Chief Executive, said: 'As we continue to see significant growth in our business, it has been necessary to expand our facilities to meet the increased demand. We are therefore delighted to announce the signing of a lease for new cutting-edge facilities at BioHub in Alderley Park. The location of the facility is ideal for transport links, both by air and road, which is important as Cyprotex expands its international footprint.'
